Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus 175/75 mg versus 75 mg in relapsed/refractory mantle cell lymphoma
NL-OMON36865Phase 4Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of temsirolimus in mantle cell lymphoma (MCL) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started May 2013; status: active, not recruiting.
02
Drugs
temsirolimus
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON36865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36865.